- Home
- CDTX vs NVAX Comparison
CDTX vs NVAX Comparison
Compare CDTX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- NVAX
- Stock Information
- Founded
- CDTX 2012
- NVAX 1987
- Country
- CDTX United States
- NVAX United States
- Employees
- CDTX 73
- NVAX N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CDTX Health Care
- NVAX Health Care
- Exchange
- CDTX Nasdaq
- NVAX Nasdaq
- Market Cap
- CDTX 1.6B
- NVAX 1.3B
- IPO Year
- CDTX 2015
- NVAX 1995
- Fundamental
- Price
- CDTX $65.32
- NVAX $7.92
- Analyst Decision
- CDTX Strong Buy
- NVAX Buy
- Analyst Count
- CDTX 11
- NVAX 7
- Target Price
- CDTX $57.00
- NVAX $14.29
- AVG Volume (30 Days)
- CDTX 489.9K
- NVAX 7.2M
- Earning Date
- CDTX 11-06-2025
- NVAX 11-11-2025
- Dividend Yield
- CDTX N/A
- NVAX N/A
- EPS Growth
- CDTX N/A
- NVAX N/A
- EPS
- CDTX N/A
- NVAX 2.54
- Revenue
- CDTX N/A
- NVAX $1,078,718,000.00
- Revenue This Year
- CDTX N/A
- NVAX $61.69
- Revenue Next Year
- CDTX N/A
- NVAX N/A
- P/E Ratio
- CDTX N/A
- NVAX $3.25
- Revenue Growth
- CDTX N/A
- NVAX 9.22
- 52 Week Low
- CDTX $10.14
- NVAX $5.01
- 52 Week High
- CDTX $69.36
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- CDTX 58.07
- NVAX 51.51
- Support Level
- CDTX $61.10
- NVAX $7.63
- Resistance Level
- CDTX $65.84
- NVAX $8.31
- Average True Range (ATR)
- CDTX 3.05
- NVAX 0.35
- MACD
- CDTX -0.42
- NVAX -0.00
- Stochastic Oscillator
- CDTX 71.23
- NVAX 68.06
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.